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Imaging-detected relapses are observed in a significant proportion of patients with medullary thyroid carcinoma (MTC) with normal
postoperative imaging studies. The aim of this study was to search for prognostic factors of imaging-detected relapse. This
retrospective study was performed in 63 consecutive MTC patients with normal postoperative medical imaging. After surgery, the
basal calcitonin (CT) level was undetectable in 35 patients and elevated in 28. During follow-up, 18 patients developed a clinical or
imaging-detected relapse (29%) in the neck and/or at distant sites: 15 had an elevated postoperative basal CT level and three had an
undetectable postoperative basal CT level. At multivariate analysis, the significant parameters predictive of imaging-detected relapse
were the postoperative plasma CT level and the tumour extension (pT). The 3- and 5-year relapse-free survival rates were 94 and
90% in patients with an undetectable postoperative basal CT level, and 78 and 61% in patients with a detectable basal CT level
(Po0.05). The 3- and 5-year relapse-free survival rates were 92 and 85% in the pT1–3 patients, and 57 and 46% in the pT4 patients
(Po0.01). These results show that postoperative CT level and tumour extension are critical prognostic factors for the identification
of patients at a high risk of relapse.
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Even following apparently complete surgical resection of medul-
lary thyroid carcinoma (MTC), the postoperative plasma calcitonin
(CT) level remains elevated in a large proportion of patients.
Elevated plasma CT indicates the persistence of neoplastic
foci. Furthermore, rare relapses have been reported in patients
with an undetectable basal CT after initial surgery (Modigliani et al,
1998).
In patients with elevated CT levels, the sensitivity of imaging
methods (including ultrasonography, computed tomography scan,
MRI or scintigraphy) for the detection of residual disease is limited
for lesions other than gross residual disease (Frank-Raue et al,
1992). Selective venous sampling catheterisation with plasma CT
measurements appears to be the most sensitive and specific
method for localising persistent disease. However, even after
further surgery based on the results of venous sampling, 62–98%
of the patients still have elevated CT levels (Frank-Raue et al, 1992;
Abdelmoumene et al, 1994; Moley et al, 1998; Kebebew et al,
2000b).
Five and 10-year overall survival rates in MTC patients without
initial distant metastases range between 60–100% and 55–100%,
respectively, suggesting that an aggressive therapeutic approach
may not be appropriate in all patients (Rougier et al, 1983; Saad
et al, 1984; Schroder et al, 1988; Raue et al, 1993; Dottorini et al,
1996; Scopsi et al, 1996; Bergholm et al, 1997; Modigliani et al,
1998). In patients with elevated plasma CT level and with no
evidence of gross residual disease after initial surgery, the rate of
clinical or imaging-detected relapses is about 40% during the
subsequent follow-up (Rougier et al, 1983; Van Heerden et al,
1990). However, prognostic factors for relapse have not been
clearly identified in these patients. The aims of our single centre
retrospective study were (1) to describe the long-term outcome of
MTC patients without clinically and imaging-detectable disease
after initial neck surgery and (2) to search for prognostic factors
for imaging-detected relapse.
METHODS
Patients
Imaging investigations (including a neck ultrasonography, a chest
computed tomography scan, an abdominal ultrasonography or an
abdominal computed tomography scan) were performed after
initial treatment in 122 MTC patients at the Institut Gustave
Roussy between 1988 and 1998. A bone scintigraphy was also
performed in patients with elevated postoperative CT levels.
Postoperative imaging was abnormal in 59 patients and normal in
63 patients. These 63 patients constitute the population in this
retrospective study. Pathologic diagnoses were all reviewed by a
single pathologist (B Caillou, Institut Gustave Roussy). Medullary
Thyroid Carcinomas were classified as either sporadic or
hereditary according to the familial history and the RET proto-
oncogene analysis. Received 7 November 2002; accepted 25 February 2003
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lymph node neck dissection (LND) was defined as a dissection of
bilateral central and lateral lymph nodes; otherwise it was
considered incomplete. Tumours were defined according to the
tumour–node–metastasis (TNM) classification (Hermanech and
Sobin, 1992, p 35) (T stands for the tumour size: T1: diame-
terp1cm; T2: diameter41cm and p4cm; T3: diameter44cm;
T4: any size but extension beyond the thyroid capsule; N stands for
the lymph node metastases: N0–without and N1–with lymph node
metastases; M stands for distant metastases: M0–without and M1–
with distant metastases). According to T, N and M, four stages are
individualised: stage I: T1N0M0; stage II: T2–4N0M0; stage III:
T1–4N1M0; stage IV: T1–4N0–1M1). In 22 patients, more than
one surgical procedure was performed within 18 months for
incomplete LND and elevated postoperative CT. Follow-up started
after the last surgical procedure. Eleven patients received post-
operative external radiation therapy to the neck.
Between 6 weeks and 3 months after surgery, plasma CT (ELSA-
CT, CIS-Bio International, Gif-sur-Yvette, France; normal range
o10pgml
 1) was measured. In 27 of the 35 patients with an
undetectable basal plasma CT, a pentagastrin stimulation test was
performed (slow intravenous injection of 0.5mgkg
 1 pentagastrin
(Peptavlon, Wyeth-Ayerst Lab; Philadelphia, PA, USA) over 3min
with CT measurements before and then 3 and 5min thereafter).
Serum carcinoembryogenic antigen (CEA) (Enzymum-test CEA,
Boehringer, Mannheim, Germany; normal o7ngml
 1) was
measured more than 2 months after surgery.
Patients were then followed up every 6 months, with a clinical
examination and measurement of CT and CEA levels. An imaging
work-up, consisting of a neck and abdominal ultrasonography, was
performed yearly. In case of elevated CT level, a chest computed
tomography scan and a bone scintigraphy were also performed
yearly. Imaging-detected relapse was defined as an abnormal
clinical or imaging examination.
Statistics
Follow-up ended on 1 January 2002. Three- and 5-year relapse-free
survival rates were calculated using the Kaplan–Meier method
(Kaplan and Meier, 1958). The Rothman method (Rothman, 1978)
was used to calculate the confidence interval (CI).
Prognostic factors for imaging-detected relapse were studied by
using univariate log-rank tests and multivariate Cox model
analyses; proportional hazard assumptions were checked using
graphical methods. The following parameters were compared: age
at diagnosis, gender, hereditary status, stage of the disease, tumour
extension (pT) (pT4 vs. pT1–3), node status (pN), percentage of
metastatic lymph node (410% vs o10% of the total number of
resected lymph nodes), postoperative basal plasma CT level
(detectable vs undetectable), external radiation therapy to the
neck and the extent of LND (complete vs incomplete). As the stage
of the disease and the percentage of metastatic lymph node are
closely linked to pT and pN, and are therefore competitive factors,
multivariate analysis was performed with only three factors: pT,
pN and postoperative basal plasma CT level.
RESULTS
Patients’ characteristics
Sixty-three consecutive patients were included in the study (35
females, 28 males; Table 1). The mean age at diagnosis was 42 years
(range, 3–72 years). Medullary thyroid carcinoma was sporadic in
44 patients and hereditary in 19 patients (familial MTC (FMTC), 6;
multiple endocrine neoplasia type 2A (MEN 2A), 9; multiple
endocrine neoplasia type 2B (MEN 2B), 4). The mean follow-up
was 6.9 years (range, 0.4–13.7 years).
A cervical LND was performed in 61 patients and was complete
in 43. Two patients underwent a thyroidectomy without LND for a
benign thyroid nodule, and a micro-MTC (4 and 5mm in diameter,
respectively) was discovered at the final pathological examination.
Postoperative basal CT levels were undetectable and no further
surgery was performed in these two cases.
Stage I MTC (T1N0M0) was diagnosed in 10 patients, stage II
(T2N0M0) in 13 patients and stage III in 40 patients (4 T1N1M0; 25
T2N1M0; 1 T3N1M0; 10 T4N1M0).
Postoperative CT and CEA levels
After surgery, basal plasma CT was elevated in 28 patients (44%)
(median: 131pgml
 1; range: 12–3772pgml
 1), whereas it was
undetectable in the other 35 patients. A pentagastrin stimulation
test was performed in 27 of these 35 patients and yielded a
detectable stimulated CT level in five (median: 125pgml
 1; range:
43–808pgml
 1). Carcinoembryogenic antigen, measured in 52
patients, was moderately elevated in six (mean: 20ngml
 1; range:
9–26ngml
 1). All patients with an elevated postoperative CEA
level also had an elevated postoperative basal CT level (mean CT:
918pgml
 1; range: 26–2000). The mean follow-up was equivalent
in patients with undetectable and elevated postoperative basal CT
levels.
Outcome
The 3- and 5-year relapse-free survival rates were 86% (CI, 75–
93%) and 79% (CI, 66–87%), respectively. An imaging-detected
Table 1 Characteristics of the 63 patients with normal postoperative imaging
All patients
Patients without
relapse (n¼45; 71%)
Patients with relapse
(n¼18; 29%)
Mean age (y) (range) 42 (3–72) 42 (3–7) 42 (11–72)
Gender: male/female 28/35 17/28 11/7
Sporadic/Hereditary MTC 44/19 30/15 14/4
(FMTC/MEN 2A/MEN 2B) (6/9/4) (6/8/1) (0/1/3)
Mean follow-up (years) (range) 6.9 (0.4–13.7) 6.6 (0.4–12.6) 7.7 (1.8–13.7)
TNM stage
I 10 10 0
II 13 12 1
III 40 23 17
Postoperative CT level: undetectable/elevated 35/28 32/13 3/15
Lymph node dissection: complete/incomplete/not done 42/19/2 30/13/2 12/6/0
Neck radiation therapy 11 7 4
Abbreviations: MTC¼medullary thyroid carcinoma; MEN¼multiple endocrine neoplasia; FMTC¼familial MTC. TNM=tumour–node–metastasis.
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(Table 2). Imaging-detected relapses were located in the neck
lymph nodes in eight patients, at distant sites in eight, and in both
the neck and at distant sites in two. An isolated neck imaging-
detected relapse developed in previously dissected areas in six
patients and in areas that had not been dissected in the other two.
Isolated distant metastases were found in the liver (five patients),
in the chest (one patient) and in bones (two patients). In the
remaining two patients, a neck imaging-detected relapse occurred
in previously dissected lymph node areas with liver metastases in
one and with liver and bone metastases in the other. Fifteen had an
elevated postoperative CT level and three had an undetectable
postoperative CT level. At the time of imaging-detected relapse,
basal CT level was below 150pgml
 1 in five patients (mean:
1481pgml
 1; range: 20–6290) and CEA level was normal in five
patients (mean: 41ngml
 1; range: 0–300).
The 3- and 5-year overall survival rates were 98% (CI, 91–100%)
and 97% (CI, 88–99%), respectively. Five patients died. One
patient with T2N0M0 disease presented a neck relapse after 6.1
years, underwent further surgery and died of respiratory failure
during the postoperative period. The other four patients died from
distant metastases after 1.8, 3.7, 6.9 and 13.7 years, respectively.
They all had stage III disease (two T2N1M0, two T4N1M0). Three
had an elevated postoperative basal CT level and one had an
undetectable postoperative basal CT level with a pentagastrin-
stimulated CT level at 162pgml
 1.
Prognostic factors for imaging-detected relapse
Univariate analysis showed that the following parameters were
significantly predictive of imaging-detected relapse (Table 3): the
stage of the disease (Po0.01), pT (Po0.001), pN (Po0.001), the
percentage of metastatic lymph nodes (Po0.01) and the post-
operative plasma CT level (Po0.001). Gender, age at diagnosis and
hereditary status of the disease were not statistically significant.
The results were not modified when postoperative external
radiotherapy and the extent of lymph node dissection were
included in the analysis.
The stage of the disease, tumour extension, node status,
percentage of metastatic lymph nodes and postoperative plasma
CT level were highly interrelated since all pT4 patients had lymph
node metastases, all had more than 10% of metastatic lymph nodes
and all except one had a detectable postoperative basal CT level.
The percentage of metastatic lymph nodes and the stage of the
disease were therefore excluded from the multivariate analysis
which was performed with only three parameters: pT, pN and
postoperative basal CT level. The independent significant prog-
nostic parameters for imaging-detected relapse were the post-
operative plasma CT level (Po0.01) and the tumour extension
(Po0.05). pN was not an independent, statistically significant
prognostic parameter (P¼0.1).
The 3- and 5-year relapse-free survival rates were 94% (CI, 80–
98%) and 90% (CI, 75–97%), respectively, in the 35 patients with
an undetectable postoperative basal CT level, and 78% (CI, 59–
90%) and 61% (CI, 41–77%), respectively, in the 28 patients with
detectable postoperative basal CT level (Po0.005) (Figure 1). An
imaging-detected relapse occurred in three of the 35 patients (9%)
with an undetectable postoperative basal CT level and in 15 of the
28 patients (54%) with an elevated postoperative basal CT level
(Table 2). In the three patients with an undetectable postoperative
CT level who relapsed, postoperative pentagastrin-stimulated CT
level was undetectable in one patient and attained 43 and
162pgml
 1 respectively in the other two.
The 3- and 5-year relapse-free survival rates were 92% (CI, 81–
87%) and 85% (CI, 72–93%), respectively, in the 53 pT1–3
patients, and 57% (CI, 28–82%) and 48% (CI, 20–74%),
respectively, in the 10 pT4 patients (Po0.001). An imaging-
detected relapse occurred in 11 patients with a pT1–3 tumour
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patients with elevated postoperative basal CT level, the 5-year
relapse-free survival rate was 84% (CI, 62–95%) in pT1–3 patients
and 35% (CI, 11–70%) in pT4 patients (Figure 2). The difference
is, however, not statistically significant (P¼0.2).
The 3- and 5-year relapse-free survival rates were both 100% in
the 23 pT1–3 N0 patients and 86% (CI, 69–94%) and 72% (CI,
52–86%), respectively, in the 30 pT1–3 N1 patients (Po0.001).
Table 3 Prognostic factors for relapse
n
3-year
relapse-free
survival (%) CI 95%
5-year
relapse-free
survival (%) CI 95% P
Stage
I 10 100 – 100 – 0.003
II 13 100 – 100 –
III 40 78 [63–89] 61 [44–76]
Tumour extension
pT1–T3 53 92 [81–87] 85 [72–93] 0.0003
pT4 10 57 [28–82] 46 [20–74]
Node
N0 23 100 – 100 [68–87] 0.0006
N1 40 78 [63–89] 65 [44–80]
Postoperative CT level
Undetectable 35 94 [80–98] 90 [75–97] 0.0009
Detectable 28 78 [59–90] 61 [41–77]
Percentage of lymph node metastases
o10% 28 100 – 90 [68–87] 0.004
X10% 26 72 [53–86] 64 [44–80]
Gender
Female 35 88 [72–95] 81 [64–91] 0.089
Male 28 85 [67–94] 76 [66–88]
Age at diagnosis
o45 years 31 83 [66–93] 79 [60–90] 0.53
X45 years 32 90 [74–97] 79 [61–90]
Hereditary disease
Yes 22 91 [71–97] 85 [63–95] 0.165
No 41 84 [70–93] 75 [59–87]
External radiation therapy
Yes 11 91 [62–98] 79.5 [48–94] 0.98
No 52 86 [73–93] 75.6 [61–86]
Lymph node dissection
Complete 42 88 [74–95] 79 [63–89] 0.86
Incomplete 21 84 [62–95] 78 [55–91]
01234567
Years from surgery
Patients at risk (n)
35 33 31 29 25 22 18 12
28 27 25 19 18 14 9 8
Undetectable
Elevated
100%
80%
60%
40%
20%
0%
log rank: P < 0.001
Figure 1 Relapse-free survival according to basal postoperative CT level.
0 1 23 4 5 6 7
Years from surgery
Patients at risk (n)
19 18 17 14 13 11 8 7
9 9 85 5 3 1 1
pT1-3
pT4
100%
80%
60%
40%
20%
0%
log rank: P = 0.183
Figure 2 Relapse-free survival in patients with elevated basal post-
operative CT level according to pT.
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Nonmetastatic MTC has a favourable prognosis. However, the 10-
year overall survival rate varied widely among series, from 55 up to
100% respectively (Rougier et al, 1983; Saad et al, 1984; Schroder
et al, 1988; Raue et al, 1993; Dottorini et al, 1996; Scopsi et al, 1996;
Bergholm et al, 1997; Modigliani et al, 1998). As therapy should be
adapted to the prognosis of the disease, the identification of
patients at high risk of relapse is essential. In the present study on
63 patients with normal postoperative imaging and either an
undetectable postoperative basal CT level or an elevated post-
operative basal CT level, the 3- and 5-year overall survival rates
were 98 and 97%, respectively. Imaging-detected relapse occurred
in 29% of the patients, and the 3- and 5-year relapse-free survival
rates were 86 and 79%, respectively. In patients with elevated
postoperative basal CT level, the 5-year relapse-free survival rate
was 61%, similar to that reported by van Heerden et al (1990).
The prognostic factors for survival of MTC patients include the
age at diagnosis, the gender and the TNM classification (Schroder
et al, 1988; Raue et al, 1993; Dottorini et al, 1996; Scopsi et al, 1996;
Bergholm et al, 1997; Modigliani et al, 1998; Kebebew et al, 2000a).
Data concerning MTC patients with normal postoperative imaging
are few. In one study where the age was below 35 years, the
presence of more than three metastatic nodes at initial surgery was
found to be a significant prognostic factor for relapse at univariate
analysis (van Heerden et al, 1990). In our study, at univariate
analysis, stage of the disease, pT, pN, percentage of metastatic
lymph nodes and postoperative basal CT level were found to be
prognostic factors for imaging-detected relapse. Owing to a high
link between stage, percentage of metastatic lymph nodes, pT and
pN, multivariate analysis was performed on pT, pN and post-
operative basal CT level. Only the postoperative basal CT level and
pT were independent prognostic factors.
Calcitonin is a highly sensitive marker of persistent disease that
is more sensitive than any other imaging modality (Frank-Raue
et al, 1992; Abdelmoumene et al, 1994). Elevated postoperative
basal CT level was described as a survival prognostic factor
(Dottorini et al, 1996; Modigliani et al, 1998). In our study, it
appeared prognostic for imaging-detected relapse. An imaging-
detected relapse occurred in 54% of the patients with an elevated
postoperative basal CT level and in 9% of the patients with an
undetectable postoperative basal CT level. Our active follow-up
permitted the early diagnosis of recurrences at a stage when basal
CT level was below 150pgml
 1 and CEA level was still in the
normal range (five patients). In patients with postoperative
undetectable basal CT level, a pentagastrin-stimulated test should
be performed, when possible. However, even an undetectable
pentagastrin-stimulated CT level does not totally exclude the risk
of relapse, and this was observed in one of our patients, in
accordance with another study (Modigliani et al, 1998). This
underlines the need for prolonged follow-up in all MTC patients.
Tumour extension is, in our study and in others, a significant
independent prognostic factor (Scopsi et al, 1996). In our study, in
the group of patients with an elevated postoperative basal CT level,
the risk of relapse was even higher when the tumour was pT4. In
this group, we did not, however, show a significant difference in
relapse-free survival, probably because of the very low number of
patients.
Node status was identified as a prognostic factor in the uni-
variate analysis in our study and in others (Schroder et al, 1988;
van Heerden et al, 1990; Raue et al, 1993; Dottorini et al, 1996;
Scopsi et al, 1996; Bergholm et al, 1997; Modigliani et al, 1998;
Hyer et al, 2000; Kebebew et al, 2000a). In another study, with
rising numbers of metastatic lymph node, gross distant metastases
occurred more frequently and postoperative basal CT level was less
often normalised (Machens et al, 2000). In our study, among pT1–
3 patients, a relapse occurred in none of the pN0 patients and in
37% of the pN1 patients. Among pT4N1 patients, a relapse
occurred in 70%. Taken together, these data suggested that both
tumour extension and nodal involvement were prognostic
indicators of relapse. However, the strong interrelation between
pT and pN was responsible for a competition between these two
factors in the multivariate analysis.
This study allowed us to identify patients with a high risk of
relapse among those with normal postoperative imaging, in whom
an aggressive therapeutic approach should be considered. In
retrospective studies, external radiation therapy to the neck was
associated with a decreased risk of local relapse with a
controversial effect on survival (Rougier et al, 1983; Samaan et al,
1988; Fersht et al, 2001). In our study, external radiation therapy
was not found to be a prognostic factor, but was performed only in
a few patients either with pT1–3 tumour or pT4 tumour.
Nevertheless, external radiation therapy should be discussed in
patients with an elevated postoperative CT level and a pT4 tumour.
As the response rate to cytotoxic treatments is below 20% and as
responses are partial and transient (Schlumberger et al, 1995),
there is no place for adjuvant chemotherapy in MTC patients with
normal imaging. It should only be given to patients with rapidly
progressive metastatic disease.
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